Q Rev Bio Dis: 新希望!MIT开发新蛋白质,或可阻止COVID-19卷起的“致命”风暴

2020-04-21 林山月 生物探索

自新型冠状病毒肺炎(COVID-19)出现以来,全世界超240万人受感染,逾16万人死亡。迄今已有多项研究表明,细胞因子风暴是导致COVID-19患者死亡的重要原因。

自新型冠状病毒肺炎(COVID-19)出现以来,全世界超240万人受感染,逾16万人死亡。迄今已有多项研究表明,细胞因子风暴是导致COVID-19患者死亡的重要原因。

当病毒入侵人体时,免疫系统将会指挥免疫细胞对其进行“绞杀”,并产生细胞因子,号召其他细胞抵御“外敌”。不过,当免疫系统应激过度时,过量的细胞因子将会召唤来更多的细胞,造成细胞因子风暴,对包括病原体在内的一切细胞进行无差别攻击,进而引发炎症、多器官功能衰竭乃至死亡。

近日,发表在《Quarterly Review of Biophysics Discovery》上的一项研究为阻止这场“夺命”风暴带来了希望。


https://doi.org/10.1017/qrd.2020.4

麻省理工学院的一个研究小组开发出了一种模仿“细胞因子受体”的水溶性蛋白质,能够吸收过量的细胞因子,有效阻止细胞因子风暴的发生,减轻患者的感染症状。

细胞因子受体是一种存在于细胞表面的跨膜蛋白,大多数不溶于水。当它和细胞因子相结合后,能够将信号传递到细胞内部。

阻止过量的细胞因子与其受体结合,或许能够有效避免具有致命性的细胞因子风暴。基于这个想法,研究人员从2019年4月开始着手设计一种能够像海绵一样吸收多余细胞因子的蛋白质。他们利用此前开发的一种被称为“QTY代码”的工具,将细胞因子受体的疏水区修饰为亲水区,使之能够溶于水,从而有效穿越人体血液。

随后,研究人员还在这个水溶性受体蛋白上附加了一个被称为Fc区的抗体片段,有助于进一步稳定血液中的蛋白质,使之免受免疫系统的攻击。

在实验中,研究人员一共设计了6种可模仿不同细胞因子受体的蛋白质,并对它们进行了实验室测试,结果发现,这些经过修饰的蛋白质能够以与天然细胞因子受体相似的强度结合到细胞因子上。

第一作者Rui Qing表示,“我们的想法是,它们(经过修饰后的蛋白质)可以被注射到体内,并与细胞因子风暴产生的过量细胞因子结合,去除过量细胞因子,缓解感染症状。”

2020年3月,当有证据揭示SARS-CoV-2病毒正在某些患者体内诱发细胞因子风暴时,研究人员意识到他们所研发的蛋白质可能有助于减轻患者的感染症状,于是快速发布了他们的研究成果,并计划在人体细胞和受到SARS-CoV-2感染的动物模型中进行测试。

目前,研究人员已经为其设计的蛋白质以及创建水溶性细胞因子受体的整体方法申请了专利。他们希望能够快速获得技术许可,并与制药和生物技术公司展开合作,从而加速使这类蛋白质应用于临床试验。

该研究的共同作者、Avalon GloboCare的首席执行官兼总裁David Jin说:“显然,这种方法将需要进一步的动物研究以及潜在的人类临床研究。但是我们有信心,这一发现将有助于临床应用来解决涉及细胞因子风暴的病毒性疾病。”

原始出处:
Shilei Hao ,et al. QTY code-designed water-soluble Fc-fusion cytokine receptors bind to their respective ligands. Quarterly Review of Biophysics Discovery. 09 April 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765827, encodeId=f1d11e65827d1, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 05 20:11:06 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900874, encodeId=4c9619008e403, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Mar 29 11:11:06 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919060, encodeId=7d1919190603d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 30 14:11:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013308, encodeId=496e201330895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 27 06:11:06 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970011, encodeId=56a519e00113e, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Sep 10 08:11:06 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297111, encodeId=7303129e11130, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 23 12:11:06 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382062, encodeId=ca333820624a, content=应该做单一炎性因子抑制剂和多炎症因子抑制剂对病毒脱落影响的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=444b1718665, createdName=QQ047a06da, createdTime=Wed Apr 22 10:53:59 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765827, encodeId=f1d11e65827d1, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 05 20:11:06 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900874, encodeId=4c9619008e403, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Mar 29 11:11:06 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919060, encodeId=7d1919190603d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 30 14:11:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013308, encodeId=496e201330895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 27 06:11:06 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970011, encodeId=56a519e00113e, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Sep 10 08:11:06 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297111, encodeId=7303129e11130, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 23 12:11:06 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382062, encodeId=ca333820624a, content=应该做单一炎性因子抑制剂和多炎症因子抑制剂对病毒脱落影响的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=444b1718665, createdName=QQ047a06da, createdTime=Wed Apr 22 10:53:59 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2021-03-29 gracezdd
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765827, encodeId=f1d11e65827d1, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 05 20:11:06 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900874, encodeId=4c9619008e403, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Mar 29 11:11:06 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919060, encodeId=7d1919190603d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 30 14:11:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013308, encodeId=496e201330895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 27 06:11:06 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970011, encodeId=56a519e00113e, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Sep 10 08:11:06 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297111, encodeId=7303129e11130, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 23 12:11:06 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382062, encodeId=ca333820624a, content=应该做单一炎性因子抑制剂和多炎症因子抑制剂对病毒脱落影响的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=444b1718665, createdName=QQ047a06da, createdTime=Wed Apr 22 10:53:59 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2020-09-30 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1765827, encodeId=f1d11e65827d1, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 05 20:11:06 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900874, encodeId=4c9619008e403, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Mar 29 11:11:06 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919060, encodeId=7d1919190603d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 30 14:11:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013308, encodeId=496e201330895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 27 06:11:06 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970011, encodeId=56a519e00113e, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Sep 10 08:11:06 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297111, encodeId=7303129e11130, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 23 12:11:06 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382062, encodeId=ca333820624a, content=应该做单一炎性因子抑制剂和多炎症因子抑制剂对病毒脱落影响的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=444b1718665, createdName=QQ047a06da, createdTime=Wed Apr 22 10:53:59 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1765827, encodeId=f1d11e65827d1, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 05 20:11:06 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900874, encodeId=4c9619008e403, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Mar 29 11:11:06 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919060, encodeId=7d1919190603d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 30 14:11:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013308, encodeId=496e201330895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 27 06:11:06 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970011, encodeId=56a519e00113e, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Sep 10 08:11:06 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297111, encodeId=7303129e11130, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 23 12:11:06 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382062, encodeId=ca333820624a, content=应该做单一炎性因子抑制剂和多炎症因子抑制剂对病毒脱落影响的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=444b1718665, createdName=QQ047a06da, createdTime=Wed Apr 22 10:53:59 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2020-09-10 珙桐
  6. [GetPortalCommentsPageByObjectIdResponse(id=1765827, encodeId=f1d11e65827d1, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 05 20:11:06 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900874, encodeId=4c9619008e403, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Mar 29 11:11:06 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919060, encodeId=7d1919190603d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 30 14:11:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013308, encodeId=496e201330895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 27 06:11:06 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970011, encodeId=56a519e00113e, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Sep 10 08:11:06 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297111, encodeId=7303129e11130, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 23 12:11:06 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382062, encodeId=ca333820624a, content=应该做单一炎性因子抑制剂和多炎症因子抑制剂对病毒脱落影响的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=444b1718665, createdName=QQ047a06da, createdTime=Wed Apr 22 10:53:59 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1765827, encodeId=f1d11e65827d1, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 05 20:11:06 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900874, encodeId=4c9619008e403, content=<a href='/topic/show?id=5f9b119599d' target=_blank style='color:#2F92EE;'>#MIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11959, encryptionId=5f9b119599d, topicName=MIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=872f168, createdName=gracezdd, createdTime=Mon Mar 29 11:11:06 CST 2021, time=2021-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919060, encodeId=7d1919190603d, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Sep 30 14:11:06 CST 2020, time=2020-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013308, encodeId=496e201330895, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 27 06:11:06 CST 2021, time=2021-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970011, encodeId=56a519e00113e, content=<a href='/topic/show?id=ec345834075' target=_blank style='color:#2F92EE;'>#新希望#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58340, encryptionId=ec345834075, topicName=新希望)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25d7319, createdName=珙桐, createdTime=Thu Sep 10 08:11:06 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297111, encodeId=7303129e11130, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 23 12:11:06 CST 2020, time=2020-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=382062, encodeId=ca333820624a, content=应该做单一炎性因子抑制剂和多炎症因子抑制剂对病毒脱落影响的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=444b1718665, createdName=QQ047a06da, createdTime=Wed Apr 22 10:53:59 CST 2020, time=2020-04-22, status=1, ipAttribution=)]
    2020-04-22 QQ047a06da

    应该做单一炎性因子抑制剂和多炎症因子抑制剂对病毒脱落影响的研究

    0

相关资讯

Chest:COVID-19住院患者死亡的危险因素分析

该研究提出的列线图可根据个人特征准确预测COVID-19患者的临床结局。对于高危患者应及早发现,加强监护和适当治疗。

RedHill与NIAID达成协议,评估RHB-107治疗COVID-19的有效性

生物制药公司RedHill近日宣布,它已与美国过敏和传染病研究所(NIAID)达成协议,向NIAID提供其研究性药物RHB-107(upamostat,WX-671)。

C5抑制剂Ultomiris(ravulizumab-cwvz)治疗重症COVID-19患者的临床试验:即将开展

Alexion制药公司近日表示,它计划启动Ultomiris(ravulizumab-cwvz)治疗COVID-19急性呼吸窘迫综合征患者的III期研究。

JAMA超详细综述:盘点COVID-19的治疗药物及临床试验进展

美国约翰斯·霍普金斯大学实时统计数据显示,截至北京时间2020年4月21日10时,全球COVID-19的确诊病例已达到247万多例。

4月21日全球新冠肺炎(COVID-19)疫情简报,累计确诊超247万例,各国病例增长趋势不同步

Worldometers世界实时统计数据显示,截至北京时间4月21日7时30分,全球新冠肺炎累计确诊病例超过247万例,达到2478406例,累计死亡病例达到170306例。美国新冠肺炎累计确诊病例全

QRB Discovery :MIT开发出新蛋白,或可阻止COVID-19患者出现细胞因子风暴

Covid-19的主要特征之一是在严重情况下可能会发生过度的免疫反应。这种免疫过度反应的爆发,也称为细胞因子风暴,会损害肺部并可能致命。细胞因子风暴始终是冠状病毒及其他严重感染患者疾病进展及死亡的重要